 |
PRESS RELEASE
BurnsAdler Licenses Anti-Epileptic Portfolio
from
Desitin Arzneimittel GmbH
Charlotte,
North Carolina (March 5, 2004) –
BurnsAdler
announced today that it has licensed three anti-epileptic
products from
Desitin Arzneimittel GmbH
(“Desitin”) for promotion in Canada, Mexico and the Caribbean
markets. The lead product is Apydan™ a twice daily
oxcarbazepine tablet. In the United States the only
oxcarbazepine on the market generated sales of over $200
million in 2003. According to IMS data, in Mexico sales of
this same product were approximately $9 million or 6% of the
$150 million Mexican anti-epileptic market.
Banks
Bourne, President of BurnsAdler remarked, “We look forward to
promoting Apydan™ as an alternative brand of oxcarbazepine in
each of our key markets. Desitin is the leader in promoting
CNS products in Germany and we are pleased to be partnering
together. They have been very successful with Timox™, their
oxcarbazepime brand in Europe, and we look forward to doing
the same in Canada and Mexico.”
Oxcarbazepine, a 10-keto analogue of
carbamazepine, is the first in a new class of high potential
anti-epileptic agents. It is effective in treating partial
seizures with or without secondary generalization, both in
mono and add-on therapy. Oxcarbazepine has favorable
pharmacological properties, both in efficacy and safety,
compared to its precursor carbamazepine. Both oxcarbazepine
and its metabolite elicit anticonvulsant activity.
BurnsAdler is
a specialty
pharmaceutical company that in-licenses and promotes products
in Europe, South America, Latin America, Canada and the
Caribbean. The company also works with select U.S. and
foreign corporations on product commercialization in the
United States. BurnsAdler’s portfolio currently includes
products in the following fields: cardiovascular, orthopedic,
anti-epileptic and hospital.
Desitin Arzneimittel GmbH is a Hamburg-based
specialty pharmaceutical company focused on central nervous
system (CNS) disorders. Founded in 1919, Desitin has a long
history of CNS pharmaceutical product innovation, and is a
leading European developer, manufacturer, marketer and
distributor of prescription pharmaceuticals for the treatment
of epilepsy and Parkinson's disease. Desitin is the market
leader for anti-epileptics in Germany.
For additional information
about this news release contact Molly Whitehurst at
+1.704.770.0994 Ext. 224. Find additional information about
BurnsAdler at
www.burnsadler.com.
|
BurnsAdler provides cost effective international product distribution and promotion for select emerging pharmaceutical companies.
 Print View
|
